Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration
Executive Summary
Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments
You may also be interested in...
Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
Roche Pegasys Has 23% Market Share; Better Luck In Rematch With Intron?
Roche's Pegasys has captured a 23% share of new prescriptions for hepatitis C in the U.S., Global Pharmaceutical Head William Burns told investors during a year-end conference in London Feb. 26
Roche Pegasys/Copegus Dosing Should Be Set By Genotype, FDA Cmte. Says
Treatment with Roche's Pegasys/Copegus should be dosed according to hepatitis C virus genotype in order to optimize the product's risk/benefit ratio, FDA's Antiviral Drugs Advisory Committee recommended